SCHEMBL1329709

SCHEMBL1329709

COC(=O)c1sc(Br)c(Br)c1F

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.48
KMT2A Q03164 3/20 0.48
HSD17B10 Q99714 3/20 0.48
TSHR P16473 3/20 0.48
IKBKB O14920 1/20 0.36
PTPN1 P18031 1/20 0.35
GPR35 Q9HC97 1/20 0.34
ALDH1A1 P00352 6/20 0.34
HPGD P15428 4/20 0.34
LMNA P02545 2/20 0.34
MAPK1 P28482 2/20 0.34
PPARG P37231 1/20 0.34
NCOA1 Q15788 1/20 0.34
NPSR1 Q6W5P4 1/20 0.34
NCOA3 Q9Y6Q9 1/20 0.34
MEN1 O00255 2/20 0.33
SOS1 Q07889 1/20 0.33
KDM4E B2RXH2 1/20 0.33
GLA P06280 1/20 0.33
GAA P10253 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27029417 0.85 MAPT (0.48) MAPTKMT2AHSD17B10TSHRIKBKB
SCHEMBL21612060 0.82 KMT2A (0.54) MAPTKMT2AHSD17B10TSHRPTPN1
SCHEMBL21858572 0.81 HSD17B10 (0.46) MAPTKMT2AHSD17B10TSHRIKBKB
SCHEMBL20598163 0.80 MAPT (0.42) MAPTKMT2AHSD17B10TSHRALDH1A1
SCHEMBL1973056 0.78 MAPT (0.50) MAPTKMT2AHSD17B10TSHRGPR35
SCHEMBL1529858 0.78 MAPT (0.50) MAPTKMT2AHSD17B10TSHRPTPN1
SCHEMBL2682770 0.77 MAPT (0.48) MAPTKMT2AHSD17B10TSHRPTPN1
SCHEMBL15537262 0.77 KMT2A (0.48) MAPTKMT2AHSD17B10TSHRPTPN1
SCHEMBL23531546 0.77 KMT2A (0.44) MAPTKMT2AHSD17B10TSHRIKBKB
SCHEMBL16065014 0.75 GPR35 (0.48) TSHRPTPN1GPR35

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11884643-B2 Substituted thiophenecarboxamides and analogues as antibacterials agents BAYER AKTIENGESELLSCHAFT (DE) 2024-01-30 US claimed
EP-3818050-B1 SUBSTITUTED THIOPHENECARBOXAMIDES AND ANALOGUES AS ANTIBACTERIALS AGENTS BAYER AG (DE) 2023-05-31 EP claimed
US-20230159506-A1 SUBSTITUTED THIOPHENECARBOXAMIDES AND ANALOGUES AS ANTIBACTERIALS AGENTS BAYER AKTIENGESELLSCHAFT (DE) 2023-05-25 US claimed
EP-3818050-A1 SUBSTITUTED THIOPHENECARBOXAMIDES AND ANALOGUES AS ANTIBACTERIALS AGENTS Bayer Aktiengesellschaft (DE) 2021-05-12 EP claimed
CN-112638893-A Substituted thiophenecarboxamides and analogs as antibacterial agents 拜耳公司 2021-04-09 CN claimed
WO-2020007905-A1 SUBSTITUTED THIOPHENECARBOXAMIDES AND ANALOGUES AS ANTIBACTERIALS AGENTS BAYER AKTIENGESELLSCHAFT (DE) 2020-01-09 WO claimed
EP-3994130-B1 SUBSTITUTED THIOPHENE CARBOXAMIDES AND DERIVATIVES THEREOF AS MICROBICIDES BAYER AG (DE) 2024-07-10 EP disclosed
CN-114364663-B Substituted thiophenecarboxamides and derivatives thereof as microbiocides 拜耳公司 2024-07-05 CN disclosed
CN-112638893-B Substituted thiophenecarboxamides and analogues as antibacterial agents 拜耳公司 2024-03-29 CN disclosed
US-11884643-B2 Substituted thiophenecarboxamides and analogues as antibacterials agents BAYER AKTIENGESELLSCHAFT (DE) 2024-01-30 US disclosed
EP-3818050-B1 SUBSTITUTED THIOPHENECARBOXAMIDES AND ANALOGUES AS ANTIBACTERIALS AGENTS BAYER AG (DE) 2023-05-31 EP disclosed
US-20230159506-A1 SUBSTITUTED THIOPHENECARBOXAMIDES AND ANALOGUES AS ANTIBACTERIALS AGENTS BAYER AKTIENGESELLSCHAFT (DE) 2023-05-25 US disclosed
CN-115667237-A Novel heterocyclic compounds as BET inhibitors 成都苑东生物制药股份有限公司 2023-01-31 CN disclosed
EP-1968568-A2 INHIBITORS OF Akt ACTIVITY SmithKline Beecham Corporation (US) 2008-09-17 EP disclosed
US-20080027048-A1 Such as 5-(3-cyano-4-n-propoxyphenyl)thiophene-2-carboxylic acid; for diseases associated with xanthine oxidase such as hyperuricemia, gout, inflammatory bowel diseases, diabetic kidney diseases, diabetic retinopathy ASTELLAS PHARMA INC. (JP) 2008-01-31 US disclosed
US-20070270458-A1 Nicotinic Acetylcholine Receptor Ligands ASTRAZENECA AB (SE) 2007-11-22 US disclosed
WO-2007076423-A2 INHIBITORS OF Akt ACTIVITY SMITHKLINE BEECHAM CORPORATION (US) 2007-07-05 WO disclosed
EP-1783124-A1 2-PHENYLTHIOPHENE DERIVATIVE Astellas Pharma Inc. (JP) 2007-05-09 EP disclosed
EP-1699786-A1 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS AstraZeneca AB (SE) 2006-09-13 EP disclosed
WO-2005061494-A1 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS ASTRAZENECA AB (SE) 2005-07-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11884643-B2 Substituted thiophenecarboxamides and analogues as antibacterials agents XDH, TST, BLVRB MAPT 4393/4885KMT2A 4407/4885HSD17B10 1993/4885
US-20230159506-A1 SUBSTITUTED THIOPHENECARBOXAMIDES AND ANALOGUES AS ANTIBACTERIALS AGENTS XDH, TST, BLVRB MAPT 4393/4885KMT2A 4407/4885HSD17B10 1993/4885
US-20070270458-A1 Nicotinic Acetylcholine Receptor Ligands CHRNA2, CHRNA1, CHRNA6 MAPT 1079/4885KMT2A 1225/4885HSD17B10 2709/4885
US-20080027048-A1 Such as 5-(3-cyano-4-n-propoxyphenyl)thiophene-2-carboxylic acid; for diseases associated with xanthine oxidase such as hyperuricemia, gout, inflammatory bowel diseases, diabetic kidney diseases, diabetic retinopathy XDH, UACA, NUDT1 MAPT 1064/4885KMT2A 3232/4885HSD17B10 699/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.